This indicates that ERCC2 mutation status could be a very important biomarker for predicting the efficacy of NAC in bladder cancer patients and thus could direct the decision-making process regarding treatment, which may benefit the patient [39]. This evidence concerns the gene ERCC2 and urinary bladder cancer.